Network Bio launched Thursday August 20, 2026 with $50 million in Series A financing. Company thesis: build AI models trained on human biological data (spanning multi-omics, single-cell sequencing, and functional genomics datasets) for drug discovery across multiple therapeutic areas. The launch adds to the rapidly expanding AI-driven peptide and biologic discovery ecosystem that also includes PeptiDream's PDPS platform (Kawasaki-based, constrained cyclic peptide focus with active partnerships across Novartis, Merck, Genentech/Roche, AbbVie, Bristol Myers Squibb, and Eli Lilly), Insilico Medicine's Pharma.AI (31 developmental candidates on the platform, $2.75 billion Lilly collaboration March 2026, $2.5 billion SK Biopharmaceuticals deal June 2026, Takeda strategic collaboration July 2026), Aizen Therapeutics' DaX foundation model (August 15 deal with San Diego public biotech worth up to $100 million per target for oral peptide therapeutics, non-canonical amino acid chemical space at 10x traditional scale), and Isomorphic Labs (Google DeepMind spinout with AlphaFold-derived structural modeling for target validation and small-molecule design). The AI drug discovery category has accumulated more than $8 billion in partnership deal value across 2026 to date, with peptide-focused platforms capturing a substantial share of the total given the growth of the peptide therapeutic modality across obesity (GLP-1 class), rare disease (setmelanotide, palopegteriparatide, vosoritide, avexitide), and oncology (peptide-drug conjugates, radioligand therapies). Network Bio's Palo Alto location adds to the West Coast AI biotech cluster that also includes Recursion, Insitro, and Isomorphic Labs.
Aizen Therapeutics announced a multi-program collaboration with a San Diego-based public biotech to design oral peptide therapeutics using its DaX foundation model. Deal terms: several million dollars in initial revenue plus up to $100 million in milestones for each nominated target. The collaboration will develop proof of activity with the DaX platform for well-known disease-relevant targets in immunology and neurology indications, with the potential to expand the roster of targets over time. The DaX platform has been trained on millions of uniquely annotated molecules and receptors and explores the non-canonical amino acid (ncAA) peptide chemical space at 10x the scale of traditional ncAA discovery methods. Non-canonical amino acids extend beyond the standard 20 natural amino acids to include modified building blocks that give peptides properties (metabolic stability, membrane permeability, oral bioavailability) that natural peptides do not have; this is essential for the oral peptide therapeutics that the collaboration targets. DaX positions Aizen as one of the more substantial AI-driven peptide discovery platforms alongside PeptiDream's PDPS system (Kawasaki-based, constrained cyclic peptide focus with active collaborations across Novartis, Merck, Genentech, AbbVie, and Eli Lilly), Isomorphic Labs (Google DeepMind spinout with AlphaFold-derived structural modeling), and Insilico Medicine's Pharma.AI (which has secured over $5 billion in partnership deal value across 2026). The collaboration adds to the growing evidence that AI-designed peptides are becoming a distinct drug discovery category with real deal-flow.
PeptiDream Inc. (TSE: 4587), the Kawasaki-based peptide discovery platform company, announced the appointment of three new Executive Vice Presidents. The leadership restructure accompanies the company's multi-year deal-book growth and the increasing preclinical-to-clinical progression of its partnered peptide programs. Company background: PeptiDream operates the Peptide Discovery Platform System (PDPS), a proprietary technology for designing constrained cyclic peptides. PDPS uses genetic-code reprogramming to generate trillion-scale diverse libraries of non-standard peptides (containing modified amino acids not found in natural proteins), which are then screened to identify molecules that bind target proteins with high affinity and specificity. Applications span oncology (peptide-drug conjugates, radioligand-conjugated peptides), immunology (novel immune-modulating peptides), and rare disease peptide drug development. Partnership book: PeptiDream has active collaborations with Novartis (multiple targets), Merck (peptide-radioligand programs), Genentech/Roche (immuno-oncology), AbbVie (multiple targets), Bristol Myers Squibb, Eli Lilly (including the recent obesity-adjacent partnership), and multiple mid-cap biopharmaceutical companies. The constrained cyclic peptide modality PeptiDream specializes in sits between traditional linear peptides (subject to protease degradation and short half-lives) and small-molecule drugs (limited target diversity), and has grown as a distinct drug modality throughout the 2020s as GLP-1 and other peptide successes have expanded the industry's willingness to invest in peptide chemistry platforms.
Alnylam Pharmaceuticals (NASDAQ: ALNY) reports Q2 2026 earnings Thursday July 30, 2026 before market open with an 8:30 AM ET conference call. Wall Street consensus estimates: EPS of $2.05 (+540.6% year-over-year) and revenue of $1.32 billion (+70.4% year-over-year), reflecting the continued commercial ramp of Amvuttra (vutrisiran) across both hereditary transthyretin amyloid polyneuropathy (hATTR-PN) and hereditary transthyretin amyloid cardiomyopathy (hATTR-CM) after the Q1 2026 Amvuttra revenue of $889.9 million (+187% YoY). Analyst focus areas beyond the base-business ramp include: the ALN-6222 first-in-human Phase 1 obesity siRNA program (NCT07624071) that opened enrollment in July 2026 as a randomized double-blind placebo-controlled single-ascending-dose study of an undisclosed-target subcutaneous siRNA in adults with BMI 30-40 kg/m²; the ALN-2232 Phase 1 obesity program (Alnylam's second obesity-track siRNA) with Phase 1 readout expected in the second half of 2026; the Alnylam-PeptiDream peptide-siRNA conjugate extrahepatic delivery platform milestone announced December 2025; and the broader Alnylam 2030 strategy launch positioning beyond the Amvuttra franchise.
Alnylam Pharmaceuticals (NASDAQ: ALNY) reports Q2 2026 earnings Thursday July 30, 2026 before market open. Analyst focus areas include the new ALN-6222 investigational subcutaneous siRNA obesity Phase 1 trial (NCT07624071, first-in-human single-ascending-dose randomized double-blind placebo-controlled design enrolling approximately 88 adults with BMI 30 to less than 40 kg/m² and HbA1c below 6.5% at a single site in Mount Royal, Canada through December 2027; molecular target of ALN-6222 has not been publicly disclosed). Also under focus: the Phase 1 ALN-2232 program (Alnylam's second obesity-track siRNA, with a Phase 1 readout expected in the second half of 2026), the Alnylam-PeptiDream peptide-siRNA conjugate extrahepatic delivery platform milestone announced December 2025 (demonstrating peptide-ligand-mediated targeted siRNA delivery to specific extrahepatic tissues), and the broader Alnylam 2030 strategy launch positioning beyond the Amvuttra (vutrisiran) transthyretin amyloidosis franchise. Alnylam's obesity pipeline is programmed against inhibin subunit beta E (INHBE) in liver and activin receptor type 1C (ACVR1C) in adipose tissue, both nucleic-acid modality targets that are distinct from GLP-1 agonism.
Asahi Kasei initiated a Phase I trial in Japan of AK1940, a selective TNF receptor 1 antagonist peptide discovered jointly with PeptiDream for autoimmune and inflammatory diseases. The trial will assess PK, safety, and tolerability of single and multiple subcutaneous doses in healthy volunteers; preclinical models showed high TNFR1 selectivity and anti-inflammatory activity without blocking TNFR2 signaling.